StreetInsider.com News Articles

Big Pharma Setbacks Create a New Wave of Rebound Plays

Thu, 10 Sep 2026 14:12:41 -0400

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The biotech tape delivered a brutal reminder of one of the sector’s oldest rules: even a fundamentally strong company can get caught in the crossfire when a major drugmaker suffers a pipeline setback. Yesterday, a setback at Novartis (NYSE: NVS) sent ripples across the biotech space, pressuring companies whose own clinical and corporate announcements remained decidedly positive.

The resulting selloff highlighted just how quickly investors can shift from company-specific fundamentals to broader sector risk. For smaller biotech names, that indiscriminate pressure can be painful, but it can also create potentially compelling

Big Pharma Setbacks Create a New Wave of Rebound Plays

Thu, 10 Sep 2026 14:12:41 -0400

Big Pharma Setbacks Create a New Wave of Rebound Plays

Thu, 10 Sep 2026 14:12:41 -0400

Big Pharma Setbacks Create a New Wave of Rebound Plays

Thu, 10 Sep 2026 14:12:41 -0400

Big Pharma Setbacks Create a New Wave of Rebound Plays

Thu, 10 Sep 2026 14:12:41 -0400

Big Pharma Setbacks Create a New Wave of Rebound Plays

Thu, 10 Sep 2026 14:12:41 -0400

Big Pharma Setbacks Create a New Wave of Rebound Plays

Thu, 10 Sep 2026 14:12:41 -0400

Big Pharma Setbacks Create a New Wave of Rebound Plays

Thu, 10 Sep 2026 14:12:41 -0400

Opus Genetics (IRD) PT Raised to $17 at Citizens

Wed, 09 Sep 2026 12:31:07 -0400

Citizens analyst Jonathan Wolleben raised the price target on Opus Genetics (NASDAQ: IRD) to $17.00 (from $12.00) while maintaining a Market Outperform rating.

Opus Genetics (IRD) PT Raised to $13 at Wedbush

Wed, 09 Sep 2026 12:25:34 -0400

Wedbush analyst Yun Zhong raised the price target on Opus Genetics (NASDAQ: IRD) to $13.00 (from $10.00) while maintaining a Outperform rating.

The analyst comments "We believe that the positive stock reaction to this morning's BEST1 update refects investors' recognition of an increased probability of success (PoS) based on an alignment with the FDA on potential pivotal study endpoints, despite Opus' decision to dose escalate in Cohort 2. Most importantly, the mean improvement from baseline of >3 decibels in microperimetry across at least 5 loci represents a significantly lowered regulatory bar vs. the FDA's historical requirement of >7 decibels at 5

Opus Genetics (IRD) PT Raised to $13 at Wedbush

Wed, 09 Sep 2026 12:25:34 -0400

Wedbush analyst Yun Zhong raised the price target on Opus Genetics (NASDAQ: IRD) to $13.00 (from $10.00) while maintaining a Outperform rating.

Four Biotech Stories Heating Up Right Now

Wed, 09 Sep 2026 11:55:26 -0400

DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies Holdings (NASDAQ:NTHI) is pairing fresh institutional capital with encouraging NEO100 clinical data; Opus Genetics (NASDAQ:IRD) is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; bioAffinity Technologies (NASDAQ:BIAF) removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; Tenon Medical (NASDAQ:TNON) eliminated roughly $5.16 million of convertible-note obligations ahead of maturity.